{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:16:29Z","timestamp":1793837789352,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10096-025-05208-3","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:20:36Z","timestamp":1752139236000},"page":"2427-2437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intravenous combined with nebulized polymyxin B may be effective in treating carbapenem-resistant gram-negative bacilli hospital-acquired pneumonia: a retrospective cohort study"],"prefix":"10.1007","volume":"44","author":[{"given":"Ye","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lexin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"5208_CR1","doi-asserted-by":"publisher","unstructured":"Miron M, Blaj M, Ristescu AI, Iosep G, Avadanei AN, Iosep DG et al (2024) Hospital-acquired pneumonia and ventilator-associated pneumonia: a literature review. Microorganisms 12. https:\/\/doi.org\/10.3390\/microorganisms12010213","DOI":"10.3390\/microorganisms12010213"},{"key":"5208_CR2","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1007\/s00134-022-06773-3","volume":"48","author":"OT Ranzani","year":"2022","unstructured":"Ranzani OT, Niederman MS, Torres A (2022) Ventilator-associated pneumonia. Intens Care Med 48:1222\u20131226. https:\/\/doi.org\/10.1007\/s00134-022-06773-3","journal-title":"Intens Care Med"},{"key":"5208_CR3","doi-asserted-by":"publisher","first-page":"e51034","DOI":"10.15252\/embr.202051034","volume":"21","author":"M Huemer","year":"2020","unstructured":"Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS (2020) Antibiotic resistance and persistence-Implications for human health and treatment perspectives. EMBO Rep 21:e51034. https:\/\/doi.org\/10.15252\/embr.202051034","journal-title":"EMBO Rep"},{"key":"5208_CR4","unstructured":"World Health Organisation (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. https:\/\/www.infobioquimica.com\/new\/wp-content\/uploads\/2017\/02\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. [Accessed 2 July 2024]"},{"key":"5208_CR5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jmii.2023.01.017","volume":"56","author":"M Zeng","year":"2023","unstructured":"Zeng M, Xia J, Zong Z, Shi Y, Ni Y, Hu F et al (2023) Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli. J Microbiol Immunol Infect 56:653\u2013671. https:\/\/doi.org\/10.1016\/j.jmii.2023.01.017","journal-title":"J Microbiol Immunol Infect"},{"key":"5208_CR6","unstructured":"China Antimicrobial Resistance Surveillance System (2024) 2023 national report on antimicrobial resistance surveillance. https:\/\/www.carss.cn\/Report\/Details\/978. [Accessed 23 June 2025]"},{"key":"5208_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","volume":"41","author":"S Yaghoubi","year":"2021","unstructured":"Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Sholeh M et al (2021) Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis 41:1003\u20131022. https:\/\/doi.org\/10.1007\/s10096-020-04121-1","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5208_CR8","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s15010-022-01876-x","volume":"50","author":"S Zhen","year":"2022","unstructured":"Zhen S, Wang H, Feng S (2022) Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections. Infection 50:1409\u20131423. https:\/\/doi.org\/10.1007\/s15010-022-01876-x","journal-title":"Infection"},{"key":"5208_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","author":"PD Tamma","year":"2024","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA (2024) Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciae403","journal-title":"Clin Infect Dis"},{"key":"5208_CR10","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1039\/c7np00023e","volume":"34","author":"F Rabanal","year":"2017","unstructured":"Rabanal F, Cajal Y (2017) Recent advances and perspectives in the design and development of polymyxins. Nat Prod Rep 34:886\u2013908. https:\/\/doi.org\/10.1039\/c7np00023e","journal-title":"Nat Prod Rep"},{"key":"5208_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A et al (2019) International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European Society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacotherapy 39:10\u201339. https:\/\/doi.org\/10.1002\/phar.2209","journal-title":"Pharmacotherapy"},{"key":"5208_CR12","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB et al (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis 63:e61\u2013e111. https:\/\/doi.org\/10.1093\/cid\/ciw353","journal-title":"Clin Infect Dis"},{"key":"5208_CR13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/00003246-198608000-00027","volume":"14","author":"JRLP LeGall","year":"1986","unstructured":"LeGall JRLP (1986) Alp\u00e9rovitch A APACHE II\u2013a severity of disease classification system. Crit Care Med 14:754\u2013764. https:\/\/doi.org\/10.1097\/00003246-198608000-00027","journal-title":"Crit Care Med"},{"key":"5208_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s13054-019-2663-7","volume":"23","author":"S Lambden","year":"2019","unstructured":"Lambden S, Laterre PF, Levy MM, Francois B (2019) The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care 23:374. https:\/\/doi.org\/10.1186\/s13054-019-2663-7","journal-title":"Crit Care"},{"key":"5208_CR15","unstructured":"London (2023) Acute kidney injury_prevention, detection andmanagement. https:\/\/www.niceorguk\/guidance\/ng148\/chapter\/Recommendations#assessing-risk-of-acute-kidney-injury.\u00a0Accessed\u00a02\u00a0Jul 2024"},{"key":"5208_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10096-020-04046-9","volume":"40","author":"Y Yin","year":"2021","unstructured":"Yin Y, Zhao C, Li H, Jin L, Wang Q, Wang R et al (2021) Clinical and microbiological characteristics of adults with hospital-acquired pneumonia: a 10-year prospective observational study in China. Eur J Clin Microbiol Infect Dis 40:683\u2013690. https:\/\/doi.org\/10.1007\/s10096-020-04046-9","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5208_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1128\/CMR.00064-16","volume":"30","author":"L Poirel","year":"2017","unstructured":"Poirel L, Jayol A, Nordmann P (2017) Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev 30:557\u2013596. https:\/\/doi.org\/10.1128\/CMR.00064-16","journal-title":"Clin Microbiol Rev"},{"key":"5208_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","volume":"48","author":"TB Tran","year":"2016","unstructured":"Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ et al (2016) Pharmacokinetics\/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents 48:592\u2013597. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.09.010","journal-title":"Int J Antimicrob Agents"},{"key":"5208_CR19","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1093\/jac\/dkx167","volume":"72","author":"M Boisson","year":"2017","unstructured":"Boisson M, Gregoire N, Cormier M, Gobin P, Marchand S, Couet W et al (2017) Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients. J Antimicrob Chemother 72:2607\u20132612. https:\/\/doi.org\/10.1093\/jac\/dkx167","journal-title":"J Antimicrob Chemother"},{"key":"5208_CR20","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1093\/jac\/dkz356","volume":"74","author":"A Benitez-Cano","year":"2019","unstructured":"Benitez-Cano A, de Antonio-Cusco M, Luque S, Sorli L, Carazo J, Ramos I et al (2019) Systemic pharmacokinetics and safety of high doses of nebulized colistimethate sodium in critically ill patients with hospital-acquired and ventilator-associated pneumonia. J Antimicrob Chemother 74:3268\u20133273. https:\/\/doi.org\/10.1093\/jac\/dkz356","journal-title":"J Antimicrob Chemother"},{"key":"5208_CR21","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.cmi.2021.01.020","volume":"27","author":"JY Feng","year":"2021","unstructured":"Feng JY, Peng CK, Sheu CC, Lin YC, Chan MC, Wang SH et al (2021) Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant gram-negative bacterial pneumonia: a multi-centre observational study. Clin Microbiol Infect 27:1465\u20131473. https:\/\/doi.org\/10.1016\/j.cmi.2021.01.020","journal-title":"Clin Microbiol Infect"},{"key":"5208_CR22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ijid.2021.06.007","volume":"108","author":"TA Almangour","year":"2021","unstructured":"Almangour TA, Alruwaili A, Almutairi R, Alrasheed A, Alhifany AA, Eljaaly K et al (2021) Aerosolized plus intravenous colistin vs intravenous colistin alone for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria: a retrospective cohort study. Int J Infect Dis 108:406\u2013412. https:\/\/doi.org\/10.1016\/j.ijid.2021.06.007","journal-title":"Int J Infect Dis"},{"key":"5208_CR23","doi-asserted-by":"publisher","first-page":"e15774","DOI":"10.1016\/j.heliyon.2023.e15774","volume":"9","author":"D Lu","year":"2023","unstructured":"Lu D, Mao W (2023) Efficacy and safety of intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of multidrug-resistant gram-negative bacterial pneumonia: a systematic review and meta-analysis. Heliyon 9:e15774. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15774","journal-title":"Heliyon"},{"key":"5208_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jinf.2018.02.002","volume":"76","author":"KZ Vardakas","year":"2018","unstructured":"Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME (2018) Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: a systematic review and meta-analysis. J Infect 76:321\u2013327. https:\/\/doi.org\/10.1016\/j.jinf.2018.02.002","journal-title":"J Infect"},{"key":"5208_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13054-023-04448-z","volume":"27","author":"T Tang","year":"2023","unstructured":"Tang T, Li Y, Xu P, Zhong Y, Yang M, Ma W et al (2023) Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study. Crit Care 27:164. https:\/\/doi.org\/10.1186\/s13054-023-04448-z","journal-title":"Crit Care"},{"key":"5208_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2478\/jccm-2020-0044","volume":"7","author":"MJ Hasan","year":"2021","unstructured":"Hasan MJ, Rabbani R, Anam AM, Santini A, Huq SMR (2021) The susceptibility of MDR-K. Pneumoniae to polymyxin B plus its nebulised form versus polymyxin B alone in critically Ill South Asian patients. J Crit Care Med (Targu Mures) 7:28\u201336. https:\/\/doi.org\/10.2478\/jccm-2020-0044","journal-title":"J Crit Care Med (Targu Mures)"},{"key":"5208_CR27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.5005\/jp-journals-10071-24767","volume":"28","author":"S Ghosh","year":"2024","unstructured":"Ghosh S, Polymyxin B (2024) Plus aerosolized colistin vs polymyxin B alone in hospital-acquired pneumonia (\u201cAEROCOL\u201d Study): a feasibility study. Indian J Crit Care Med 28:792\u2013795. https:\/\/doi.org\/10.5005\/jp-journals-10071-24767","journal-title":"Indian J Crit Care Med"},{"key":"5208_CR28","doi-asserted-by":"publisher","first-page":"105328","DOI":"10.1016\/j.phrs.2020.105328","volume":"163","author":"M Sisay","year":"2021","unstructured":"Sisay M, Hagos B, Edessa D, Tadiwos Y, Mekuria AN (2021) Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res 163:105328. https:\/\/doi.org\/10.1016\/j.phrs.2020.105328","journal-title":"Pharmacol Res"},{"key":"5208_CR29","doi-asserted-by":"publisher","first-page":"1209063","DOI":"10.3389\/fphar.2023.1209063","volume":"14","author":"Z Wu","year":"2023","unstructured":"Wu Z, Zhang S, Cao Y, Wang Q, Sun K, Zheng X (2023) Comparison of the clinical efficacy and toxicity of nebulized polymyxin monotherapy and combined intravenous and nebulized polymyxin for the treatment of ventilator-associated pneumonia caused by carbapenem-resistant gram-negative bacteria: a retrospective cohort study. Front Pharmacol 14:1209063. https:\/\/doi.org\/10.3389\/fphar.2023.1209063","journal-title":"Front Pharmacol"},{"key":"5208_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2023.2184346","volume":"21","author":"A Ardebili","year":"2023","unstructured":"Ardebili A, Izanloo A, Rastegar M (2023) Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy? Expert Rev Anti Infect Ther 21:387\u2013429. https:\/\/doi.org\/10.1080\/14787210.2023.2184346","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5208_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jgar.2018.07.003","volume":"15","author":"MFA Abdelsalam","year":"2018","unstructured":"Abdelsalam MFA, Abdalla MS, El-Abhar HSE (2018) Prospective, comparative clinical study between high-dose colistin monotherapy and colistin-meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist 15:127\u2013135. https:\/\/doi.org\/10.1016\/j.jgar.2018.07.003","journal-title":"J Glob Antimicrob Resist"},{"key":"5208_CR32","doi-asserted-by":"publisher","first-page":"106880","DOI":"10.1016\/j.ijantimicag.2023.106880","volume":"62","author":"LZW Qiao","year":"2023","unstructured":"Qiao LZW, Yang Y, Liu X, Wang Q, Yu J, Wu J, Xu T, Jiang J, Zhang B, Long Y (2023) Clinical outcomes and safety of intravenous polymyxin B-based treatment in critically ill patients with carbapenem-resistant acinetobacter baumannii nosocomial pneumonia. Int J Antimicrob Agents 62:106880. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106880","journal-title":"Int J Antimicrob Agents"},{"key":"5208_CR33","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, Tangden T, Bitterman R, Bonomo RA et al (2022) European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 28:521\u2013547. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025","journal-title":"Clin Microbiol Infect"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05208-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05208-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05208-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:45:46Z","timestamp":1759239946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05208-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["5208"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05208-3","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Review Committee of The Second Affiliated Hospital of Zhejiang Chinese Medical University (Approval No. ZJTCMU2AE2023R081-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}